Table 2.
Clinical outcome.
| Value | n | |
|---|---|---|
| PFS1 | ||
| Median (range) | 2.9 (1.0–10.0) months | 17 |
| PFS2 | ||
| Median (range) | 7.8 (1.6–26.5) months | 20 |
| PFSr | ||
| Median (range) | 2.3 (0.2−16.4) | 17 |
| Mean | 3.6 | 17 |
| mPFSr | ||
| Median (range) | 2.7 (0.2−12.0) | 17 |
| Mean | 5.0 | 17 |
Overview including PFS1, PFS2, PFSr, mPFSr, depicting respective median and mean values. For three patients, PFS1 could not be determined since there was no progression reported. Modified PFS ratio (mPFSr), prePFS and postPFS were calculated as described by Mock et al.34
PFS1 progression-free survival time 1 (last systemic treatment prior to application of a recommended therapy), PFS2 progression-free survival time 2 (recommended therapy), PFSr PFS ratio.